anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Essential Hypertension: Verapamil produces its antihypertensive effect by a combination of vascular and cardiac effects. It acts as a vasodilator with selectivity for the arterial portion of the peripheral vasculature. As a result the systemic vascular resistance is reduced and usually without orthostatic hypotension or reflex tachycardia. Bradycardia (rate less than 50 beats/min) is uncommon. During isometric or dynamic exercise verapamil does not alter systolic cardiac function in patients with normal ventricular function.

Verapamil does not alter total serum calcium levels. However, one report has suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil.

Verapamil regularly reduces the total systemic resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles.

Electrophysiologic Effects: Electrical activity through the AV node depends, to a significant degree, upon the transmembrane influx of extracellular calcium through the L-type (slow) channel. By decreasing the influx of calcium, verapamil prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner.

Normal sinus rhythm is usually not affected, but in patients with sick sinus syndrome, verapamil may interfere with sinus-node impulse generation and may induce sinus arrest or sinoatrial block. Atrioventricular block can occur in patients without pre-existing conduction defects [see Warnings and Precautions (5.5)].

Verapamil does not alter the normal atrial action potential or intraventricular conduction time, but depresses amplitude, velocity of depolarization, and conduction in depressed atrial fibers. Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract. Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].

Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis. It is not known whether this action is important at the doses used in man.

Hemodynamics: Verapamil reduces afterload and myocardial contractility. In most patients, including those with organic cardiac disease, the negative inotropic action of verapamil is countered by reduction of afterload and cardiac index remains unchanged. During isometric or dynamic exercise, verapamil does not alter systolic cardiac function in patients with normal ventricular function. In patients with severe left ventricular dysfunction (e.g., pulmonary wedge pressure above 20 mm Hg or ejection fraction less than 30%), or in patients taking beta-adrenergic blocking agents or other cardiodepressant drugs, deterioration of ventricular function may occur [see Drug Interactions (7.4)].

Pulmonary Function: Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.

Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.
Lithium carbonate will be dosed on a flat scale of mg/day and not by weight or body surface area (BSA). Lithium carbonate will be provided as a 300mg tablet and will be taken daily without breaks in treatment.
The present invention is drawn to disinfectant or sterilant compositions and associated methods of use. In one embodiment, an aqueous disinfectant or sterilant composition can comprise an aqueous vehicle, including water, from 0.001 wt % to 50 wt % of a peracid, and from 0.001 wt % to 25 wt % of a peroxide. Additionally, from 0.001 ppm to 50,000 ppm by weight of a transition metal based on the aqueous vehicle content can also be present. The disinfectant composition can be used in the manufacture of disinfectant wipes, disinfectant gels, and disinfectant fogs. In one embodiment, the composition can be substantially free of aldehydes. Alternatively or additionally, the transition metal can be in the form of a colloidal transition metal.
Monoclonal antibody (I) to a membrane protein of human cells is new. (I) binds to a TNF receptor and so neutralises the known effects of TNFalpha and/or TNFbeta, esp. cytotoxic and cytostatic effects, expression of HLA genes and immune stimulation of T-lymphocytes and natural killer cells. (I) is antibody H298, expressed from the hybridoma cell line ECACC 90021617. The cell line, and proteins which have the same binding specificity as the antibody, are also claimed. The antibody is produced by fusing myeloma cells with spleen- or B-cells of a mouse, which has been hyperimmunised with affinity-purified TNF receptor material from human cells.
Automated healthcare information exchange. The healthcare information may comprise one or more dose orders corresponding to dose medications to be administered to a patient. The healthcare information may be received (e.g., from an EMR system such as a hospital information system (HIS) or the like) in the form of a healthcare information data stream. The information may then be standardized in to a standardized intermediate form. For instance, data may be parsed from the data stream and used to populate a staging table. In turn, data from the staging table may be transformed into an input format specific to a given dose fulfillment client to which the dose order is provided for fulfillment of the dose. Additionally, exception processing. logistical processing, and management functionality may be applied to the dose orders.
Metronomic chemotherapy-based combinations have received interest for relapsed/refractory malignancies. Preclinical and clinical studies showed activity of metronomic etoposide and axitinib. We report our retrospective experience in six children treated with axitinib and metronomic etoposide for refractory/relapsed brain tumors as an "off-label" combination. Three patients with medulloblastoma experienced partial response; one patient with atypical teratoid rhabdoid tumor (ATRT) displays an ongoing stable disease (12 months); two patients with medulloblastoma had progressive disease. Grade 3-4 toxicities were observed in two patients (thrombocytopenia, anemia, diarrhea, fatigue). The axitinib-etoposide combination shows signals of efficacy in heavily pretreated patients with relapsed/refractory brain tumors. These results were based on real-world observation and will need formal evaluation in a phase I/II trial.
Patients receive standard of care HDMTX IV over 4 hours on day 1 of weeks 4, 5, 9, and 10. After 24 hours after the start of each HDMTX infusion, patients also receive glucarpidase IV over 5 minutes in the absence of disease progression or unacceptable toxicity.
In utero infection and maternal inflammation can adversely impact fetal brain development. Maternal systemic illness, even in the absence of direct fetal brain infection, is associated with an increased risk of neuropsychiatric disorders in affected offspring. The cell types mediating the fetal brain response to maternal inflammation are largely unknown, hindering the development of novel treatment strategies. Here, we show that microglia, the resident phagocytes of the brain, highly express receptors for relevant pathogens and cytokines throughout embryonic development. Using a rodent maternal immune activation (MIA) model in which polyinosinic:polycytidylic acid is injected into pregnant mice, we demonstrate long-lasting transcriptional changes in fetal microglia that persist into postnatal life. We find that MIA induces widespread gene expression changes in neuronal and non-neuronal cells; importantly, these responses are abolished by selective genetic deletion of microglia, indicating that microglia are required for the transcriptional response of other cortical cell types to MIA. These findings demonstrate that microglia play a crucial durable role in the fetal response to maternal inflammation, and should be explored as potential therapeutic cell targets.
Hirschsprungs disease is found in 1:5000 newborns, the disease is caused by aganglionosis of the colon, leading to severe constipation and possible bowel obstruction. The diagnosis is based on leveling biopsies taken from the rectum and colon. Treatment is supportive if complications had arisen, and surgical for definitive correction of the pathophysiological condition which is the cause of the disease. Currently, clinicians rely on histopathology, for diagnosing the disease, and planning surgical correction. The main goal of Surgical treatment will be the creation of a continuous patent and innervated bowel, in which effective propulsive peristalsis is taking place. This is achieved by resection of aganglionic colon, and anastomosis of normal colon with normal ganglia, to anus. Today surgeons await histopathology report for the diagnosis of Hirschsprungs disease, and frozen section biopsies taken when in surgery to ascertain the level of ganglionated bowel.

In this study the investigators aim to correlate electrophysiological reading, from colon suspected of Hirschsprungs disease. If correlation is found, or a specific pattern which is diagnostic of the disease may be found, the electrophysiological study may offer a new way of diagnosing the disease, which is not invasive and allows prompt diagnosis in contrast to histopathology which is time consuming. A reliable electrophysiological study for Hirschsprungs disease may be helpful in early and correct diagnosis, with a noninvasive procedure as compared to a biopsy of the colonic wall. Children with chronic constipation, suspected of having hirschsprungs disease, who are admitted for rectal biopsy will be included in the study. During the procedure, electrophysiological reading from the site chosen for biopsy will be done. Correlation between electrophysiological data and histopathology will be analyzed. The actual reading will be carried out by a custom made electrode by GAELTEC DEVICES LTD : DUNVEGAN : ISLE OF SKYE : SCOTLAND.
Patients receive abiraterone acetate as in Arm I. Patients eat a high fat breakfast on day 3, and a low fat breakfast on day 10.
The invention discloses a health drink capable of improving the sleep and a preparation method of the health drink. The health drink is prepared from the following raw materials: valeriana officinalis, crowndaisy chrysanthemum, poria cocos, herba rhodobryi rosei, dregea yunnanensis, nigella damascene, cobaea scandens, calceolaria crenatiflora, Polygala tricornis Gagnep.[P.floribunda Dunn;P.congesta Rehd.et Wils.;P.yunnaensis Chodat], radix salviae miltiorrhizae, cortex albiziae, asarum caulescens maxim, bulbophyllum levinei, radix scrophulariae, faber bauhinia branchlet root, vernonia cinerea, bigbract bulbophyllum, fermented soybean, stem of gordon euryale, grass-leaved eria, snake melon, stem of Dendrobium densiflorum Lindl ex Wall., Eria corneri Reichb.f.[E.goldschmidtiana Schltr.;E.septemlamellaHayata], ginseng leaves and honey. The health drink has the beneficial effects that the health drink is mild in property, excellent in mouth taste, and suitable for people of all ages, can have the remarkable effects after short-term drinking, has the efficacies of calming the mind and soothing the nerves, is prepared from pure natural Chinese herbal medicines which have the homology of medicine and food, is safe and free of toxic and side effects, easy and convenient to prepare, and is low in cost.
The present invention discloses a new medicine for treating psoriasis-'Wulong pills' and 'Wulong injection' which are two preparations prepared through one prescription. The present invention is a pure traditional Chinese medicine preparation which is prepared from traditional Chinese medicine decoction pieces of garter snake, honeysuckle flower, kakuda figwort root, dyer woad leaf, etc. by a conventional method. The present invention has the efficacy of nourishing Yin, cooling blood, removing toxin, moistening dryness, removing patches, relieving itching, etc. The state of psoriasis can be controlled in a short time, and the psoriasis can be changed better and then cured. The effect can be taken after the medicine is taken for three to seven days, and the psoriasis can be cured after one two three days; the effective rate is more than 95%, and the clinical cure rate can reach 80%. If the psoriasis recurs after being cured, the state of the psoriasis can be effectively controlled by immediately taking the medicine. The present invention is an ideal medicine for treating psoriasis.
After observing the response to initial therapy with oxaprozin tablets, the dose and frequency should be adjusted to suit an individual patient’s needs. In osteoarthritis and rheumatoid arthritis and juvenile rheumatoid arthritis, the dosage should be individualized to the lowest effective dose of oxaprozin tablets to minimize adverse effects. The maximum recommended total daily dose of oxaprozin tablets in adults is 1,800 mg (26 mg/kg, whichever is lower) in divided doses. In children, doses greater than 1,200 mg have not been studied. 

Patients with low body weight should initiate therapy with 600 mg once daily. Patients with severe renal impairment or on dialysis should also initiate therapy with 600 mg once daily. If there is insufficient relief of symptoms in such patients, the dose may be cautiously increased to 1,200 mg, but only with close monitoring [see Clinical Pharmacology (12.3)]. 

In adults, in cases where a quick onset of action is important, the pharmacokinetics of oxaprozin allows therapy to be started with a one-time loading dose of 1,200 mg to 1,800 mg (not to exceed 26 mg/kg). Doses larger than 1,200 mg/day on a chronic basis should be reserved for patients who weigh more than 50 kg, have normal renal and hepatic function, are at low risk of peptic ulcer, and whose severity of disease justifies maximal therapy. Physicians should ensure that patients are tolerating doses in the 600 mg to 1,200 mg/day range without gastroenterologic, renal, hepatic, or dermatologic adverse effects before advancing to the larger doses. Most patients will tolerate once-a-day dosing with oxaprozin tablets, although divided doses may be tried in patients unable to tolerate single doses.
Patients will be placed in targeted temperature controlled at 33°C for 24 hours. Then, intervention will be proceeded after randomization: slowly rewarmed (0.25°C/h) to targeted temperature controlled at 37°C for 24 hours.
BACKGROUND: Tight control of type 2 diabetes (T2DM) in frail older adults has shown to be associated with adverse outcomes. The objective of this study is to determine the prevalence of tight glycemic control based on underlying frailty status and its association with functional and cognitive measures in community-dwelling older adults.
METHODOLOGY: Ancillary study of the Singapore Population Health Studies on older adults aged ≥65 years with T2DM. Tight glycemic control cut-offs were based on the 2019 Endocrine Society guideline using HbA1c target range based on a patient's overall health status measured by the FRAIL scale. Data on basic demographics, frailty, cognitive, and functional statuses were collected. Multivariable regression was used to assess potential factors associated with tight glycemic control.
RESULTS: Of 172 community-dwelling older adults with diabetes mellitus and HbA1c done, frail (65%) and pre-frail (64.4%) participants were more likely to have tight glycemic control than robust participants (31.6%, P < 0.001). In multi-variate analysis, frailty (OR 6.43, 95% CI 1.08-38.1, P = 0.041), better cognition (OR 1.15, 95% CI 1.02-1.32, P = 0.028), and multi-morbidity (OR 7.36, 95% CI 1.07-50.4, P = 0.042) were found to be significantly associated with increased odds of tight glycemic control.
CONCLUSION: Tight glycemic control was highly prevalent in frail and pre-frail older adults, especially in those with multi-morbidity and better cognition. Future prospective longitudinal studies are required to evaluate effectiveness of frailty screening in making treatment decisions and long-term outcomes. Key messages What is already known on this topic:  There is growing recognition that glycemic targets should be adjusted based on health or frailty status. However, there is no consensus on how health status or frailty should be defined when determining glycemic control targets. What this study adds:  Our study found that tight glycemic control was highly prevalent in frail and pre-frail older adults. Our findings highlight the importance of assessing for tight glycemic control based on frailty status and further work is needed to aid implementation of screening and intervention policies to avoid the attendant harms of tight glycemic control.
This invention discloses a lysin that can kill many species of Streptococci. A new lysin, ClyR, was constructed by the gene splicing method. The ClyR can effectively kill different species of Streptococci, including  Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus suis, Streptococcus uberis, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus mutans, Streptococcus equi , and various Enterococci and  Staphylococcus aureus . ClyR shows good stability and is not sensitive to EDTA and high concentration of NaCl. Moreover, the ClyR is active in a wide range of pH and maintains high activity in pH 5-11. Recombinant protein ClyR is well expressed in  E. coli  stain BL21 (DE3). High doses of ClyR showed no apparent toxicity in mice. Furthermore, administration of 0.8 mg per mouse once is able to completely protect the mouse infected with lethal doses of Group B Streptococci. The ClyR can be used alone or in combination with different forms of reagents and solutions, for the control of a variety of Streptococci and for the treatment of infections caused by these bacteria. It has a broad application prospect.
The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR(respiratory rate)(timer for 1 minute); HR (heart rate) and SpO2(oxygen saturation) through pulse oximetry in infants without atelectasis.
This was a group of 8 junior high school students who received SML in school for handwriting difficulty during the 2012-13 School Year. The participants received left eye-and-ear occlusion, fitness exercises, fine motor speed training, and handwriting practice on their right hand only.
Matching placebo for Group/dose level 2a. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
The invention discloses a nymphaea hybrid extract, a preparation method thereof, nymphaea hybrid water containing the same and lotus moisturizing Shu Minshui. This extract of nymphaea hybrid contains amino acids and mineral elements and no pigments. The nymphaea hybrid extract is obtained by firstly carrying out hot extraction on nymphaea hybrid in water, and then carrying out decoloration and membrane treatment. The obtained nymphaea hybrid extract has good antioxidant effect, safety and stability. Simple operation and low cost. In the invention, the nymphaea hybrid water and lotus moisturizing Shu Minshui are obtained based on the nymphaea hybrid extract. The obtained nymphaea hybrid water has instant and long-acting moisturizing effect and remarkably improved silky skin feeling. The obtained lotus moisturizing Shu Minshui is mild and non-irritant to skin, and has good moisturizing effect.
Type 2 diabetes mellitus is a disorder of diverse aetiology characterised by hyperglycemia resulting from abnormalities of insulin action, insulin production, or both, and the global population with diabetes mellitus is expected to be around 439 million by 2030 . Diabetic nephropathy is the most prevalent microvascular consequence of DM. It develops in around 40% of DM patients.

Obesity, which has now reached pandemic ratios, is frequently accompanied by diabetes mellitus type 2 because they share common pathophysiological pathways . Abdominal obesity is found to be a negligent form of obesity with dangerous consequences. It has been identified as potentially hazardous factor for diabetic complications. Several abdominal obesity measures have been developed including the visceral adiposity index (VAI) , lipid accumulation product (LAP) , neck circumference (NC), waist-to-hip ratio (WHR) Lipid accumulation product (LAP) and visceral adiposity index (VAI) are new, non-imaging indicators of visceral adiposity measured using body mass index (BMI), waist circumference (WC), and serum lipid profile. It was predicted in some studies that LAP and VAI have a stronger association with poor renal outcomes than BMI and WC.
Despite bilateral hippocampal damage dating to the perinatal or early childhood period and severely impaired episodic memory, patients with developmental amnesia continue to exhibit well-developed semantic memory across the developmental trajectory. Detailed information on the extent and focality of brain damage in these patients is needed to hypothesize about the neural substrate that supports their remarkable capacity for encoding and retrieval of semantic memory. In particular, we need to assess whether the residual hippocampal tissue is involved in this preservation, or whether the surrounding cortical areas reorganize to rescue aspects of these critical cognitive memory processes after early injury. We used voxel-based morphometry (VBM) analysis, automatic (FreeSurfer) and manual segmentation to characterize structural changes in the brain of an exceptionally large cohort of 23 patients with developmental amnesia in comparison with 32 control subjects. Both the VBM and the FreeSurfer analyses revealed severe structural alterations in the hippocampus and thalamus of patients with developmental amnesia. Milder damage was found in the amygdala, caudate, and parahippocampal gyrus. Manual segmentation demonstrated differences in the degree of atrophy of the hippocampal subregions in patients. The level of atrophy in CA-DG subregions and subicular complex was more than 40%, while the atrophy of the uncus was moderate (-24%). Anatomo-functional correlations were observed between the volumes of residual hippocampal subregions in patients and selective aspects of their cognitive performance, viz, intelligence, working memory, and verbal and visuospatial recall. Our findings suggest that in patients with developmental amnesia, cognitive processing is compromised as a function of the extent of atrophy in hippocampal subregions. More severe hippocampal damage may be more likely to promote structural and/or functional reorganization in areas connected to the hippocampus. In this hypothesis, different levels of hippocampal function may be rescued following this variable reorganization. Our findings document not only the extent, but also the limits of circuit reorganization occurring in the young brain after early bilateral hippocampal damage.